Our social media profiles including Twitter (@s1biopharma), Facebook (https://www.facebook.com/s1biopharma), and LinkedIn (https://www.linkedin.com/company/s1-biopharma) provide exciting opportunities to connect and interact with individuals and organizations interested in our company. We intend to use these platforms to share company news and announcements, provide corporate information and live updates from medical conferences, and participate in important community outreach and advocacy efforts.
It is our goal to interact with as many social media users as possible when appropriate, but please note we may not be able to reply individually to all messages received on these platforms. Social media posts from independent users do not necessarily reflect the views of S1 Biopharma and we reserve the right to block or mute users posting inappropriate or offensive material at our sole discretion, with or without notice. If we choose to follow a Twitter account or “Like” a Facebook page, or a user follows or “Likes” our social media properties, these actions are not an endorsement of the content those users post independently.
Because we work in a highly regulated healthcare industry we may often be unable to engage in some discussions about products or therapeutic options and will not offer medical advice. If you have a question or comment related to our products, email us at firstname.lastname@example.org or call (201) 283-9050.
If you believe you have experienced an adverse event or side effect related to an S1 Biopharma product, please contact your healthcare provider immediately. You can also visit the FDA safety information and adverse reporting program online at http://www.fda.gov/Safety/MedWatch/. If you are participating in a clinical study, please report adverse events as required in the study protocol. If you post information on social media about an adverse event or side effect, please note we may be required to contact you for additional information to comply with regulatory guidelines.